Pre-Close trading update

    RNS Number : 4367L
  Inion Oy
  12 January 2009
   


    



    Inion Oy
    ("Inion or the "Company")

    Pre-Close trading update

    Tampere, Finland and Guildford, UK. 12 January 2009, Inion (LSE: IIN.L), a company focused on the development and commercialisation of
novel biodegradable medical implants, provides an update on 2008 trading, ahead of its preliminary results announcement expected in March
2009.

    Based on the unaudited figures for the year to 31 December 2008, the Directors anticipate that revenues for 2008 will be approximately
EUR5.8 million against market expectations of approximately EUR6.0 million. This represents a 10% overall increase on 2007 revenues, which
were EUR5.2 million, while the core business of spine and speciality orthopaedics saw growth of 19% compared to 2007.

    In the US, sales from the core business in Q4 2008 were up 255% compared to the previous quarter. This compares with sales growth of 88%
from Q2 to Q3 and 81% from Q1 to Q2. Revenues in Q4 were driven by the rapidly accelerating sales of key products for spinal surgery which
received market clearance in the USA in July 2008.

    Chris Lee, CEO of Inion, said: "Inion product sales in our core business areas of spine and speciality orthopaedics have continued to
gain momentum, particularly in the USA, but also in our other key territories. This sales growth provides us with confidence in the
underlying customer demand for our unique biodegradable product offering. While we continue to seek additional funding to support our
strategy, progress made during 2008 gives us the belief that the commercial operation we have built will continue to drive revenue growth
and movement towards profitability."

    -ends-

    For further information, please contact:

    Inion Oy 
    Chris Lee, Chief Executive Officer
    Julien Cotta, Chief Financial Officer
    Tel: [phone]

    Citigate Dewe Rogerson
    Mark Swallow / Helena Galilee / David Dible    
    Tel: [phone]

    About Inion (www.inion.com)

    Inion Oy is a medical devices company focused on the development and successful commercialisation of innovative and unique biodegradable
and bioactive surgical implants in selected high value orthopaedic market segments. 

    Inion's core expertise and technology lies in the design and manufacture of innovative biodegradable plates, screws, pins and membranes,
which are used to enhance the healing of bone or soft tissue injuries to the skeleton, such as those caused by trauma or by reconstructive
surgery. Inion implants are made from its proprietary Inion family of biomaterials, with properties tailored for specific surgical
applications, in terms of strength, flexibility and rate of degradation

    Inion is also focused on developing proprietary new bioactive and biodegradable biomaterials that promote bone healing and accelerate
patient rehabilitation.

    Inion was incorporated in early 2000 and listed on the Official List of the UK Listing Authority in December 2004 (ticker: IIN). The
Company has offices in the UK and US, and its head office, R&D and production facilities are in Tampere, Finland.

    This announcement includes "forward-looking statements" which include all statements other than statements of historical facts,
including, without limitation, those regarding the Group's financial position, business strategy, plans and objectives of management for
future operations (including development plans and objectives relating to the Group's products), and any statements preceded by, followed by
or that include forward-looking terminology such as the words "targets", "believes", "estimates", "expects", "aims", "intends", "will",
"can", "may", "anticipates", "would", "should", "could" or similar expressions or the negative thereof. Such forward-looking statements
involve known and unknown risks, uncertainties and other important factors beyond the Group's control that could cause the actual results,
performance or achievements of the Group to be materially different from future results, performance or achievements expressed or implied by
such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Group's present and future business strategies and the environment in which the Group
will operate in the future. Among the important factors that could cause the Group's actual results, performance or achievements to differ
materially from those in forward-looking statements include those relating to Inion's funding requirements, regulatory approvals, reliance
on third parties, intellectual property, key personnel and other factors. These forward-looking statements speak only as at the date of this
announcement. The Group expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking
statements contained in this announcement to reflect any change in the Group's expectations with regard thereto or any change in events,
conditions or circumstances on which any such statements are based. As a result of these factors, prospective investors are cautioned not to
rely on any forward-looking statement.



This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
TSTCKCKKOBKDPDK